Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis
ConclusionsWe found significantly inferior OS in ICI-treated cancer patients with elevated pre-treatment sPD-L1 levels, but this association seems to be tumor type dependent. In addition, sPD-L1 increases during anti-PD-L1 therapy seems to be therapy specific.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Asbestosis | Cancer | Cancer & Oncology | Databases & Libraries | Esophagus Cancer | Immunotherapy | Kidney Cancer | Lung Cancer | Melanoma | Mesothelioma | Non-Small Cell Lung Cancer | Renal Cell Carcinoma | Skin Cancer | Study